India’s 1st COVID-19 Vaccine - COVAXIN™, Developed by Bharat Biotech gets DCGI approval for Phase I & II Human Clinical Trials

Bharat Biotech has successfully developed COVAXIN™, India’s 1st vaccine candidate for COVID-19, in

collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The

indigenous, inactivated vaccine developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety

Level 3) High Containment facility located in Genome Valley, Hyderabad, India.

https://www.bharatbiotech.com/images/press/Indias-1st-COVID-19-Vaccine-COVAXIN-Developed-by-Bharat-Biotech-gets-DCGI-approval-for-Phase-I-and-II-Human-Clinical-Trials.pdf

Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the study’s primary efficacy endpoints.

https://web.archive.org/web/20201118120708/https://investors.pfizer.com/investor-news/press-release-details/2020/Pfizer-and-BioNTech-Conclude-Phase-3-Study-of-COVID-19-Vaccine-Candidate-Meeting-All-Primary-Efficacy-Endpoints/default.aspx

FDA Authorizes First COVID-19 Test for Self-Testing at Home

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the first COVID-19 diagnostic test for self-testing at home and that provides rapid results. The Lucira COVID-19 All-In-One Test Kit is a molecular (real-time loop mediated amplification reaction) single use test that is intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19.

https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-covid-19-test-self-testing-home